Search
Choriogonadotropin alfa
go.drugbank.com/drugs/DB00097ApprovedInvestigationalThe primary structure of the alpha-chain of r-hCG is identical to that of the alpha-chain of hCG, FSH and LH.
Vorasidenib
go.drugbank.com/drugs/DB17097ApprovedInvestigational[A264209] It works by suppressing the levels of D-2-hydroxyglutarate (2-HG), an oncometabolite produced by mutant IDH1 and IDH2 isoforms.
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesOlutasidenib
go.drugbank.com/drugs/DB16267ApprovedInvestigationalcommon in different types of cancer, such as gliomas, AML, intrahepatic cholangiocarcinoma, chondrosarcoma, and myelodysplastic syndromes (MDS), and they lead to an increase in 2-hydroxyglutarate (2-HG
Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitorsRelatlimab
go.drugbank.com/drugs/DB14851ApprovedInvestigational[L41305] As immune checkpoint inhibitors have limited efficacy when used alone, drugs like relatlimab have been trialed in combination with other checkpoint inhibitors - for example, PD-1 inhibitors like … [A246155] Relatlimab received FDA approval in March 2022, alongside the PD-1 inhibitor [nivolumab] in the combination product Opdualag (Bristol-Myers Squibb), for the treatment of unresectable or metastatic
Avelumab
go.drugbank.com/drugs/DB11945ApprovedInvestigationalAvelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitorsVusolimogene oderparepvec
go.drugbank.com/drugs/DB23008ApprovedInvestigational] The FDA granted vusolimogene oderparepvec-wtpg accelerated approval on August 6, 2026, in combination with nivolumab for adults with unresectable advanced cutaneous melanoma that progressed on a PD … L64062] It is the second oncolytic viral therapy approved in the United States, following talimogene laherparepvec (T-VEC, Imlygic) in 2015, and the first approved for melanoma that has progressed on anti-PD
Datopotamab deruxtecan
go.drugbank.com/drugs/DB16410ApprovedInvestigational-1/PD-L1 inhibitor therapy. … [L64775] On July 29, 2026 it extended the authorization to first-line treatment of adults with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy
Categories: P-glycoprotein substratesLovastatin
go.drugbank.com/drugs/DB00227ApprovedInvestigational[A174553] More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase,[A181421] which catalyzes the conversion of HMG-CoA to mevalonic acid
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsAnthrax immune globulin human
go.drugbank.com/drugs/DB09057ApprovedInvestigationalThis binding of antibody to PA prevents PA-mediated cellular entry of toxic factors. … Available as the product Anthrasil (FDA), the result is a solution for slow IV infusion containing polyclonal antibodies that bind the protective antigen (PA) component of Bacillus anthracis lethal and
Cerivastatin
go.drugbank.com/drugs/DB00439ApprovedWithdrawnOn August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from this chol...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP2B6 Inducers